We next included data from untreated CeD patients (participant variables in Table S5 in the Supporting Information) to assess which phenotypic markers of gluten‐specific CD4+ T cells, in addition to CD39,[8] that can differentiate recently activated cells (of gluten challenged CeD) from chronically activated cells (of untreated CeD). This evidence concerns the gene ENTPD1 and cranioectodermal dysplasia.